Fern Lazar
Global Health Practice Leader, Finn Partner
Fern Lazar
Global Health Practice Leader, Finn Partner
Steven Lester
Founder, CMO, Mayo Clinic
Steven Lester, MD
Founder, CMO, Mayo Clinic
Amanda DePalma
Board of Directors SVP, Head of Corporate and Regional Marketing, Ultrasound at Siemens Healthineers
Amanda DePalma
Board of Directors SVP, Head of Corporate and Regional Marketing, Ultrasound at Siemens Healthineers
Santosh Prabhu
Divisional Vice President of Product Development for Abbott's Structural Heart Business, Abbott
Santosh Prabhu, PhD
Divisional Vice President of Product Development for Abbott's Structural Heart Business, Abbott
Product: TRICLIP™ G4 SYSTEM
Company: Abbott
About the Product:
George Yao
Franchise Head, R&D Vision Care, Alcon, Inc.
George Yao
Franchise Head, R&D Vision Care, Alcon, Inc.
Product: TOTAL30® Soft Contact Lenses
Company: Alcon, Inc.
About the Product:
TOTAL30® contact lenses by Alcon represent a groundbreaking advancement in biomaterial technology. As the first and only monthly replacement lenses to feature both Water Gradient and Celligent® Technology, they offer unparalleled comfort and ocular health. The innovative Celligent® Technology, inspired by the ocular surface biology, provides resistance to lipid and bacterial adhesion, essential for monthly lenses. TOTAL30® lenses mimic the corneal glycocalyx with a unique surface polymer structure, ensuring high lubricity and biocompatibility. TOTAL30® lenses deliver outstanding comfort and vision quality for a full 30 days.
Russ Joseph
THV Research and Development, Edwards Lifesciences
Russ Joseph
THV Research and Development, Edwards Lifesciences
Product: Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent
Company: Edwards Lifesciences
About the Product:
The Edwards SAPIEN 3 Transcatheter Pulmonary Valve (TPV) system combines the proven SAPIEN 3 transcatheter heart valve and the Alterra adaptive prestent to expand transcatheter therapy options for congenital heart valve disease patients who previously faced multiple open-heart surgeries over the course of their lives. The Alterra prestent compensates for variations in size and morphology of the right ventricular outflow tract to provide a stable landing zone for the SAPIEN 3 valve, expanding the range of patients who can now be treated with minimally invasive pulmonary valve replacement, and potentially reducing the number of invasive procedures these patients must endure.
Product: Edwards SAPIEN 3 Ultra RESILIA Transcatheter Aortic Heart Valve
Company: Edwards Lifesciences
About the Product:
The SAPIEN 3 Ultra RESILIA combines Edwards’ 40 years of tissue expertise with the market-leading SAPIEN 3 Ultra transcatheter valve and delivers patients with severe symptomatic Aortic Stenosis crucial improvements: a less invasive alternative to surgery with the potential for a longer lasting valve. RESILIA tissue’s advanced anti-calcification technology has in recent studies demonstrated freedom from structural valve deterioration at 7 years. As one of the leading causes of SVD, addressing calcification is key to overcoming questions of TAVR durability and providing thousands of patients with the confidence to choose the therapy that fits their needs.
David Taylor
Senior Vice President, R&D, Edwards Lifesciences
David Taylor
Senior Vice President, R&D, Edwards Lifesciences
Product: Edwards EVOQUE Transcatheter Tricuspid Valve Replacement System
Company: Edwards Lifesciences
About the Product:
As the global leader in patient-focused medical innovations for the treatment of structural heart disease, Edwards Lifesciences developed the EVOQUE Transcatheter Tricuspid Valve Replacement System. An estimated 1.5 million US patients suffer with moderate/worse Tricuspid Regurgitation. The EVOQUE system is FDA approved and indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team. Four hundred randomized patients were enrolled in the TRISCEND II pivotal trial with one-year outcomes to be presented at TCT 2024 in a late-breaking clinical trial session.
Mike Blue
CEO and President, HistoSonics
Mike Blue
CEO and President, HistoSonics
Product: Edison Histotripsy System
Company: HistoSonics Inc.
About the Product:
The Edison Histotripsy System uses a novel form of focused sound energy to produce controlled acoustic cavitation, called histotripsy, that mechanically destroys and liquefies targeted liver tissue instantaneously, including tumors, at subcellular levels. The Edison System uses proprietary technology and advanced imaging to deliver personalized, noninvasive treatments with precision and control, allowing most patients to return to normal activity immediately after a single treatment. The Edison System has been shown to meaningfully impact the lives of patients with the current liver tumor application, but has significant potential with expanded uses in kidney, pancreas, prostate, brain, and others significant diseases.
Ishu V. Rao
Medical Director, Impulse Dynamics
Ishu V. Rao, MD
Medical Director, Impulse Dynamics
Product: Optimizer® Smart Mini System
Company: Impulse Dynamics
About the Product:
The Optimizer® Smart Mini delivers CCM® therapy to the heart, intended to improve heart contraction by sending electrical pulses to heart cells during the absolute refractory period, allowing more oxygen-rich blood to be pumped throughout the body. The treatment is indicated for HF patients having an LVEF ranging from 25 to 45% to enhance their quality of life by achieving the 6-minute hall walk and reducing HF symptoms, such as shortness of breath, fatigue, swelling, chest pain, and more. Impulse Dynamics completed numerous clinical studies and several controlled trials. CCM therapy has been published in over 120 peer-reviewed journal articles.
Ali Dianaty
Senior Vice President, Product Innovation and Operations, Medtronic
Ali Dianaty
Senior Vice President, Product Innovation and Operations, Medtronic
Product: MiniMed™ 780G system
Company: Medtronic
About the Product:
The Medtronic MiniMed™ 780G system is the first and only FDA-approved automated insulin delivery system featuring a novel Meal Detection™ technology algorithm* that automatically adjusts† doses of insulin every 5 minutes§, bringing diabetes technology one step closer to mimicking a healthy pancreas. *Taking a bolus 15 – 20 min before a meal helps to keep blood sugar levels under control after eating. † Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off. § Refers to SmartGuard™ feature. Individual results may vary
Jason Fontana
General Manager of the Renal Denervation (RDN) Business and Vice President of CRDN Global Marketing, Medtronic
Jason Fontana
General Manager of the Renal Denervation (RDN) Business and Vice President of CRDN Global Marketing, Medtronic
Product: Symplicity Spyral™ Renal Denervation System
Company: Medtronic
About the Product:
The Medtronic Symplicity Spyral™ renal denervation (RDN) system, approved by the U.S. Food & Drug Administration (FDA) in November 2023, is one of the most thoroughly tested cardiovascular interventional devices coming to market, backed by real-world evidence in more than 25,000 patients worldwide. Symplicity Spyral is the first catheter-based approach using radiofrequency energy to complement medications and lifestyle modifications to help reduce blood pressure. Using a first-of-its-kind design, it effectively works to reduce high blood pressure numbers, creating the opportunity for millions of patients to regain peace of mind with a safe and effective treatment option to enhance their quality of life.
Hiten Chawla
Vice President, Medtronic
Hiten Chawla
Vice President, Medtronic
Product: Inceptiv™ SCS
Company: Medtronic
About the Product:
Inceptiv™ is spinal cord neurostimulator with real-time, sensing-enabled dosing for chronic pain relief. Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time, keeping therapy in harmony with the motions of daily life.
Samuel Mazin
Co-founder and CTO, RefleXion Medical
Samuel Mazin
Co-founder and CTO, RefleXion Medical
Product: RefleXion® X1 with SCINTIX® biology-guided radiotherapy
Company: RefleXion Medical
About the Product:
SCINTIX® biology-guided radiotherapy is a novel therapy that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to direct external-beam radiotherapy to single or multiple tumors. SCINTIX therapy is cleared for use in FDG-directed treatment of primary or metastatic lung and bone tumors. For the first time, SCINTIX expands the scope of radiotherapy to treat metastatic patients who often are not candidates for radiotherapy due to the extent of their disease. This brings the proven safety, efficacy, and cost-effectiveness of radiotherapy to metastatic patients who desperately need new treatment options while also treating early-stage cancer patients.
Vishal Jayakumar
SVP Robotics & Enabling Technologies R&D, Global Research and Development, Smith & Nephew, Inc.
Vishal Jayakumar
SVP Robotics & Enabling Technologies R&D, Global Research and Development, Smith & Nephew, Inc.
Product: CORI Surgical System
Company: Smith & Nephew, Inc.
About the Product:
The CORI surgical robotics platform by Smith+Nephew revolutionizes orthopedic surgery with its advanced, miniaturized handheld robotics for partial, total, and revision knee procedures, eliminating the need for a bulky robotic arm. Unique in its use of a robotic digital tensioner, CORI ensures precise soft tissue balancing. It is the only platform offering both image-free and image-based solutions for knee and hip surgeries. With AI-powered personalized knee planning and 3D hip simulation pre-planning, CORI optimizes surgical outcomes, potentially reducing hip dislocation risks and enhancing patient quality of life through tailored intra-operative adjustments.